Group items tagged

Multiple myeloma is a type of cancer that forms a type of white blood cell called a plasma cell. In multiple myeloma, cancerous plasma cells gather around the bone marrow and crowd out healthy cells. Some of the most common symptoms of multiple myeloma are pain in the back or bones, anemia, fatigue, and kidney damage. Multiple myelomas can be identified by a biopsy, which is conducted when tissue samples from the affected area are taken and examined under a microscope. When multiple myelomas are detected on an examination, it is typically very easy to remove them with a scalpel, and in many cases, surgeons will opt to remove only one lobe of tissue at a time. There has the development of various multiple myeloma drugs over the years with key industry players being involved in continuous research and development activities. Selinexor is one of the latest U.S. FDA-approved drug for multiple myeloma and is used to treat people suffering from relapsed or refractory disease. Furthermore, Ixazomib is the first and only oral proteasome inhibitor, indicated for multiple myeloma treatment. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/multiple-myeloma-drugs-are-getting.html

Epilepsy also referred to as a seizure disorder in which nerve cell activity in the brain is disturbed causing seizures. Over 50 million cases of epilepsy are observed across the globe with 80% of them living in emerging economies. Generally, epilepsy is treated by medication, while some cases require surgery, devices, or dietary changes. Over the years, various antiepileptic drugs have been approved and introduced in the market. Each new antiepileptic medication is well tolerated and shows statistically significant improvements in seizure frequency over time compared to pretreatment. However, these medications each carry their own set of challenges and limitations that must be addressed to patients taking them. Carbamazepine, a member of the benzodiazepine class, is antiepileptic drugs used to treat patients with symptomatic epilepsy and other forms of non-epilepsy epilepsy. It is typically administered intravenously or intramuscularly. Patients must be carefully monitored for allergic reactions and heart and blood pressure effects. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/antiepileptic-drugs-are-getting-better.html

These days, one of the biggest problems that are faced by the people in the whole world is drug addiction. In fact, it has been seen that most of the people are addicted to prescription drugs rather than illegal drugs...

The increasing awareness regarding the ill effects of drug abuse along with the increased stringency of regulations to prohibit drug abuse is expected fuel the innovations and market growth.

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis. In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/starpharma-holdings-limited-received.html

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Scientists while performing various researches to discover new treatments for various diseases generate and analyse vast amount of information related to drugs and indications. Discovery informatics utilizes various methods and approaches to in creating such knowledge base and help analyse such huge database to derive valuable insights used in drug discovery process.

Surge in prevalence of genitourinary disorders is expected to boost the industry during the forecast period.Increase in number of pipeline drugs for genitourinary disorder is also expected to propel the market growth in coming years.Furthermore, surge in number of generics launched by big pharmaceutical companies as well as small and medium-sized drug manufacturers are anticipated to help the industry gain higher revenue in the next few years.

Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.

Rationale for Clinical Trial Regulations Clinical trials, as we all know, are carried out to test the efficacy of a new drug or device being developed for a specific condition or disease. Clinical trials are experiments that have a high degree of risk if they are not properly implemented. For this reason, it is necessary for regulatory bodies to regulate clinical trials. The core rationale for regulating the various stages of clinical trials is that human subjects, who are part of the research, have to be protected. These clinical trial regulations are legislated at all stages: local, State, national and international. Clinical trial regulations are in force in different countries of the world. Common clinical trial regulations are also made globally by the International Conference on Harmonization (ICH), which has the mandate of setting out good practices for clinical trial regulations for trials done in global cooperation. These regulations cover the administrative, procedural and ethical aspects of clinical trials. Briefly, these are the areas in which there are clinical trial regulations for each of these aspects of clinical trials: Administrative: The administrative aspects of clinical trial regulations pertain to the way the clinical trials are run, and the way they are tracked and monitored throughout their lifecycle. A clinical trial is usually monitored by a sponsoring company or a Contract Research Organization (CRO), which the former hires at times for reasons of convenience and cost cutting. Clinical trial regulations in this area is obviously of importance because if something goes wrong at any administrative stage; these can be rectified. Procedural: Procedural aspects of clinical trial regulations relate to ways by which subjects are chosen for a clinical trial. Proper care has to be taken to ensure that the subjects are appropriate for the clinical study, are from the prescribed age, geographical, demographic, racial and gender-related cl

Course "Marketing Products without Getting Hammered by FDA" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: With this seminar you will learn how to navigate FDA's legal requirements and its interpretations for enforcement purposes. The agency now applies the principles of cognitive psychology to aid in its determination of what a message really conveys. This becomes a new factor in trying to stay within FDA's legal corral. This conference will provide insight on how to manage your marketing activity and gauge what regulatory risks your business is willing to accept. You will learn how corporate management requires cooperation between marketing, regulatory affairs, legal counsel, manufacturing, engineering and finance departments. You will understand that a weak link in any department leaves the entire corporation vulnerable to FDA enforcement. Most importantly, you will understand the boundaries that FDA uses and how easy it is to cross them. With information from this course, you can step back and rationally evaluate your firm's regulatory profile for advertising and promotion. Why should you attend: If you go "off label" with advertising and promotion, you become embroiled in FDA's advertising and promotion requirements. For devices, the law is weak and lacks legal clarity. For drugs, FDA's law and regulations are extensive and have violated Constitutional protections. Depending on your point of FDA's promotion and advertising requirements can help you or hurt you? There is an inherent conflict in interests. In any case, you need to identify practical criteria to make marketing decisions. That begs the question of whether or not marketing managers and regulatory affairs managers will even try to agree on an issue. FDA's Center for Devices and Radiological Health (CDRH) has never issued a comprehensive guidance on advertising and promotion. You are on your own. CDER has esta

The Physician Payment Sunshine Act: The Physician Payment Sunshine Act, also called Physician Payments Act, is a piece of legislation passed by the American Congress in 2010. It came to be enacted along with the Affordable Care Act, or Obamacare. The purpose of this legislation is to ensure transparency in the financial relationships that exist between the pharmaceutical industry, teaching hospitals, and physicians. What the Sunshine Act requires is this: Manufacturers of drugs and medical devices, and organizations that purchase in groups (Group Purchasing Organizations or PGO's) have to report payments or their equivalent that they make to physicians and teaching hospitals. Items that are considered equivalent to money payments, transfers of which have to be reported are clearly mentioned. These include the following: Meals Honoraria or grants Gifts Entertainment Speaking fees Writing services, such as research papers or manuscripts Travel reimbursements Purchase of items such as teaching materials and journals, which are paid either directly to physicians or teaching hospitals, supplied either directly or through a third party Funding for research Another core reporting requirement: Another requirement of the Sunshine Act is that when manufacturers of drugs and medical devices and group purchasing organizations have physicians who have a stake in some or another form in their organizations; this has to be reported to the Centers for Medicare and Medicaid Services (CMS). These reporting requirements apply to all kinds of physicians, who are either specialists or are general practitioners. However, the following are excluded from reporting by the Sunshine Act: Nurses Support and office staff Residents Medical students Physicians assistance Advance practice nurses Physicians need not report: The Sunshine Act requires information about these payments and transfers to be made by the paying medical device and drug companies, and not by physicians.

Overview: Health care practitioners and other licensed professionals work in today's diverse, fast-changing, multidisciplinary environment. All licensed professions have higher rates of drug abuse, alcohol abuse, and mental health issues. Yet each individual profession has a unique, though similar, state laws which govern how state licensing agencies take action against the professional so as to protect the public. The state's authority and power over licensed professionals often presents challenges to the impaired practitioner that are not easy to navigate. All licensed professionals must adhere to standards of state law which govern their professional practices and include prohibitions for impaired practice - even impairment along that is apart from any direct professional harm. Complaints that are received and investigated by a state agency leave the licensed professional with an uncertain process to handle the state action against them. Coupled with numerous related consequences, such as loss of employment, family issues and divorce, and criminal actions, the licensed professional must handle all these challenges successfully. Learn to identify and understand varying state laws that apply to allow disciplinary action against the licensed professional, both immediately and temporarily, and those which are permanent and final. Review the most common successful elements of the rehabilitation of the licensed professional faced with the deadly consequences of addiction. Compare and contrast regulatory laws and due process requirements for state action. This allows the licensed professional to avoid career-ending sanctions and to defend successfully against legal actions which may result in ruinous practice and career consequences for the professional. This program offers an objective, thorough review of laws which apply to the impaired licensed professional. Why should you attend: Health care practitioners are faced with a higher lifetime risk of drug abuse,

A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. Biologic drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Biologics drugs are derived from a wide variety of natural sources such as human, animal, or microorganisms by using biotechnology. Moreover, Biologics include a wide variety of products such as blood and blood components, vaccines, tissues, allergenic, gene therapy, somatic cells, and recombinant therapeutic proteins. Novel therapies and new technologies are emerging to create new biologics, which holds a prominent future for the biologics market. The market is majorly driven by the increasing prevalence of chronic diseases across the globe, growing capital investment by key players, and higher acceptability and increasing demand for innovative therapies. For instance, according to the National Health Council, around 157 million Americans are expected to have more than one chronic disorder by 2020. Moreover, according to the World Health Organization, diabetes, cancer, and cardiovascular diseases account for around 1.6 million, 9 million, and 17.9 million deaths each year, respectively. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/11/increasing-prevalence-of-chronic.html

Hepatitis and Hepatitis C are two of the most common forms of hepatitis and both are caused by different viral strains. Various companies are involved in developing a new drug for treating Hepatitis C due to the growing patient pool. The disease is caused by a virus that can be transmitted from person to person and can be acquired either through ingesting an infected person's blood or inhaling their infected air. Hepatitis is caused by a strain of the virus which is not transmitted from one person to another and is caused by a genetic defect. Hepatitis is caused by the human papillomavirus (HPV), while hepatitis C is caused by a variety of different strains of the virus called HCV. Hepatitis can be caused by a single strain of the virus, although some cases have been known to be caused by multiple strains. It is also possible for a person to contract one form of the virus, then develop a secondary infection which is caused by another form of the virus. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/hepatitis-c-drug-is-gaining-prominence.html

Ovarian Cancer Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Ovarian Cancer. Research report covers all the ongoing drug development in various phases.

Penalties and consequences of DUI (driving under the influence of alcohol or drugs) in Florida state include fines, loss of licenses, vehicular immobilization, increase rate of insurance fees, community service, and even jail time…

Biopharmaceuticals contract manufacturing refers to pharmaceutical companies outsourcing the development and manufacturing of drugs. It is driven by the use of advanced technologies, scientific advances, and d a highly complex research and development enterprise. It provide wide range of manufacturing services to biopharmaceutical companies. Biopharmaceutical contract manufacturing is widely used due to the complexity in manufacturing of biomolecules, as are considerably more complex, different in shape, size, and behavior than pharmaceuticals. Contract manufacturing organizations (CMOs) provide services from development of biologics to commercial scale production. Biopharmaceutical contract manufacturing involves the production of medicines in small units that can be customized to meet customer specifications. Contract manufacturers usually produce high quality and highly secure pharmaceuticals at low prices. The primary components of these drugs are plant materials and chemical substances. Biopharmaceutical companies are focused on producing numerous pharmaceuticals for the pharmaceutical industry. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/03/biopharmaceutical-contract.html